Clinical Research Management Office

CRMO Home | Equipment & Fees | Educational Resources | Publications | Schedule

Publications

2003

Esteva FJ, Glaspy J, Baidas S, Laufman I, Hutchins I, Dickler M, Tripathy D, Coeh R, DeMichele A, Yocim RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD: Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6): 999-1006.

Hwang JJ, Marshall JL, Rizvi N: Combined inhibition of topoisomerases: a phase I study of irinotecan and epirubicin. Oncology (Williston Park). 2003 May; 17 (5 Suppl 5): 46-51.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Guray CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003 Jun 1; 21(11): 2059-69.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-64.

Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003; 9:124-33.

Weinfurst KP, Castell LD, Li Y, Sulmasy DP, Balshem AM, Benson AB 3rd, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ: The correlation between patient characteristics and expectation of benefit from phase I clinical trials. Cancer. 2003 Jul 1; 98(1): 166-75.

2004

Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol 2004;22:398-403.

Marshall JL, Eisenberg SG, Johnson MD, Hanfelt J, Dorr FA, El-Ashry D, Oberst M, Fuxman Y, Holmlund J, Malik S: A Phase II study of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2004 Nov; 4(4): 268-74.

Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H: A phase I study of oral BMS-275291, a novel non hydroxymate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004 Mar 15; 10(6): 1963-70.

Rudkin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanasaki S, Kasid UN, Ratain MJ: Delivery of a liposomal C-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 1; 10(21): 7244-51.

Shields AF, Zalupski MM, Marshall JL, Meropol NJ: treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial: Cancer. 2004 Feb 1; 100(3): 531-7.

Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, et al.: A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 2004; 10:7583-91.

Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, et al.: A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. Clin Cancer Res 2004; 10: 8332-40.

2005

Isaacs C, Slack R, Gehan E, Ballen K, Boccia R, Areman E, Kramer R, Hayes DF, Herscowitz H, Lippman M: A multicenter randomized clinical trial evaluating interleukein-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high-risk breast cancer patients. Breast Cancer Res treat. 2005 Sep: 93(2): 125-34.

Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinea-CEA(6D): TRICOM with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005 Feb 1; 23(4): 720-31.

Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ: Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1): 31-7.

Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes DF, Isaacs C. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23: 6919-30.

2006

Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN: Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res. 2006 Feb 15; 12(4): 1251-9.

Lou E, Marshall J, Aklilu M, Cole D, Chang D, Morse M: A Phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal cancer. Clinical Colorectal Cancer. 5: 368-71, 2006.

2007

Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, Van Besien K, Zlenenetz AD, Cheson BD, Canellos GP: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007 Jun; 18(6): 1071-9.

Blum KA, Johnson JL, Niedzwiecki D, Canellos GD, Cheson BD, Bartlett NL: Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007 Jul; 48(7): 1313-9.

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007 Oct 20; 25(30): 4779-86.

Kaufman HL, Kim-Schulze S, Mason K, DeRaffele G, Mitchum J, Seo KS, Kim DW, Marshall J: Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007 Nov 26; 5:60.

Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forrero-Torres A, Chieffo N, Mckinney B, Finucone D, Molina A: A Phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory follicular lymphoma. Ann Oncol. 2007 Jul; 18(7): 1216-23.

Marcom BK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli A, Mann G, Tao Y, Ellis MJ: The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007 Mar; 102(1): 43-9.

Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ: Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21): 3055-60.

Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20, 25(30): 4793-9.

2008

Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008 Mar 20; 26(9): 1544-52.

Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H. Frankel SR, Randolph SS, Cheson BD: Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large B-cell lymphoma. Ann Oncol. 2008 May; 19(5): 964-9.

Dawson NA, Halabi S, Du SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ; Cancer and Leukemia Group B: A Phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008 Sep; 6(2): 110-6.

Friedberg JW, Cohen P, Chen L, Robinson KS, Forrero-Torres A, La Casce AS, Fayed LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008. Jan 10; 26(2): 204-10.

Fuchs CS, Marshall J, Banueaco J: Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008 Feb 1; 26(4): 689-90.

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Haganstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG: A randomized IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2008 Dec 19.

Kaufman HL, Lenz HJ, Marshall J, Singh D, Garrett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, et al: Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008 Aug 1; 14(15): 4843-9.

Lai R, Bartlett NL, Mackey JR, Jung SH, Johnson JL, Cook JR, Jones D, Cass CE, Young JD, Said J, Cheson B, His ED: High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubisin- a CALGB 59804 correlative study. Leuk Lymphoma. 2008 Jun; 49(16): 1202-5.

Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, van den Abbeeke AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12): 1993-9.

O'Brien SM, Claxton DF, Crump M, Faderi S, Kipps T, Keating MJ, Viallet J, Cheson BD: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan BCL-2 family antagonist in patients with advanced chronic lymphocytic leukemia. Blood 2009 Jan 8; 113(2): 229-305.

Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008 Sep 20; 26)27): 4473-9.

Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreef M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G: A Phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematological malignancies. Clin Cancer Res. 2008 Dec 15; 121 (24): 8295-301.

Smith SM, Grinblatt B, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD: Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol. 2008 Feb; 140(3): 313-9.

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP: A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9): 1084-9.